Aptevo reports 21% of frontline AML patients advance to stem cell transplant in RAINIER trial
Aptevo Therapeutics said that ten of 47 newly diagnosed AML patients treated with mipletamig, venetoclax and azacitidine progressed to allogeneic stem cell transplant, representing 21% of the cohort. The company noted the same outcome occurred in only 0.7% of patients receiving venetoclax and azacitidine alone in the VIA VIA‑A trial. Aptevo plans to finish dose‑optimization in the RAINIER study by year‑end 2026 and move to a Phase 2 trial in early 2027.
Why it matters
The company expects the transplant rate to demonstrate the triplet’s potential to achieve deep remissions, which could strengthen its clinical profile and support upcoming regulatory discussions. Analysts may view the data as a catalyst for the stock as the trial progresses toward Phase 2.
Key facts
- 1Ten of 47 patients advanced to stem cell transplant. stocktitan.net
- 2The ten patients represent 21% of the frontline AML cohort. tradingview.com
- 3In the VIALE‑A trial, 0.7% of patients receiving venetoclax and azacitidine alone reached transplant. tradingview.com
- 4Aptevo expects to complete dose‑optimization in the RAINIER trial by year‑end 2026. stocktitan.net
- 5The company plans to start a Phase 2 trial in early 2027. tradingview.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.